ATE495751T1 - Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper - Google Patents

Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper

Info

Publication number
ATE495751T1
ATE495751T1 AT02726672T AT02726672T ATE495751T1 AT E495751 T1 ATE495751 T1 AT E495751T1 AT 02726672 T AT02726672 T AT 02726672T AT 02726672 T AT02726672 T AT 02726672T AT E495751 T1 ATE495751 T1 AT E495751T1
Authority
AT
Austria
Prior art keywords
pancreatic cancer
monoclonal antibody
treating pancreatic
antibody fragments
binding
Prior art date
Application number
AT02726672T
Other languages
English (en)
Inventor
Myron Arlen
Kwong Tsang
Original Assignee
Neogenix Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neogenix Oncology Inc filed Critical Neogenix Oncology Inc
Application granted granted Critical
Publication of ATE495751T1 publication Critical patent/ATE495751T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Acoustics & Sound (AREA)
  • Peptides Or Proteins (AREA)
AT02726672T 2001-03-15 2002-03-15 Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper ATE495751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27628401P 2001-03-15 2001-03-15
PCT/US2002/009193 WO2002074251A2 (en) 2001-03-15 2002-03-15 Monoclonal antibody therapy for pancreas cancer

Publications (1)

Publication Number Publication Date
ATE495751T1 true ATE495751T1 (de) 2011-02-15

Family

ID=23056011

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726672T ATE495751T1 (de) 2001-03-15 2002-03-15 Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper

Country Status (9)

Country Link
US (6) US20060228363A1 (de)
EP (3) EP1411962B1 (de)
JP (1) JP2004537976A (de)
AT (1) ATE495751T1 (de)
CA (1) CA2441042A1 (de)
DE (1) DE60238987D1 (de)
DK (1) DK1411962T3 (de)
ES (2) ES2619313T3 (de)
WO (1) WO2002074251A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421070A1 (en) 2000-09-01 2002-03-14 International Bioimmune Systems, Inc. The identification and development of specific monoclonal antibodies to squamous cell carcinoma
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
CA2571743A1 (en) * 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
DE602006019565D1 (de) * 2005-03-31 2011-02-24 Biomedics Inc Monoklonaler anti-cd20-antikörper
EP2334704A1 (de) * 2008-09-09 2011-06-22 Oregon Health and Science University Für neoplastische pankreaszellen spezifische monoklonale antikörper
EP2585476A4 (de) 2010-06-22 2014-01-22 Neogenix Oncology Inc Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
EP3336104A1 (de) * 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanisierte monoklonale antikörper und verfahren zur verwendung zur diagnose und behandlung von darm- und pankreaskrebs
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
KR102131371B1 (ko) * 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
BR112016007037B1 (pt) * 2013-10-01 2023-12-26 National Cancer Center Método para detectar câncer pancreático
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10617262B2 (en) 2016-09-28 2020-04-14 San Jamar, Inc. Cutting board systems
US10617261B2 (en) 2016-09-28 2020-04-14 San Jamar, Inc. Cutting board systems
US10856699B2 (en) 2017-05-10 2020-12-08 Scott Jackson Collins Cutting board
AU2019221544B2 (en) 2018-02-13 2025-07-10 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
USD858224S1 (en) 2018-05-02 2019-09-03 Scott Jackson Collins Cutting board
USD857468S1 (en) 2018-05-02 2019-08-27 San Jamar, Inc. Cutting board
WO2025212534A1 (en) * 2024-04-05 2025-10-09 Board Of Regents, The University Of Texas System Monoclonal antibodies neutralizing marburg and ravn virus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4713352A (en) * 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4404350A (en) 1982-07-07 1983-09-13 General Electric Company Silicone-imide copolymers and method for making
DE3379203D1 (en) 1982-07-14 1989-03-23 Battelle Development Corp Method for producing cross-linked resin coatings on substrates
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
ZA858371B (en) * 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3854821T2 (de) * 1987-02-19 1996-05-23 Scripps Clinic Res Zellenoberflachenmarker für humanen Pankreaskrebszellen
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69033142T2 (de) 1989-12-22 1999-12-23 E.I. Du Pont De Nemours And Co., Wilmington Ortsspezifische rekombination von dns in pflanzenzellen
CA2110799A1 (en) * 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
CA2075343A1 (en) * 1991-08-06 1993-02-07 Nahoko Sato Monoclonal antibody and uses of the same
WO1995003828A1 (en) * 1993-08-02 1995-02-09 Houston Biotechnology Incorporated Single-chain immunotoxin compositions and methods for preventing secondary cataracts
US5665848A (en) * 1996-05-20 1997-09-09 Dow Corning Corporation Crosslinkers for silazane polymers
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2813427B1 (fr) 2000-08-25 2002-11-29 St Microelectronics Sa Circuit de commande d'une memoire dram
JP2004537976A (ja) * 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
US20040176320A1 (en) 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance
KR100466197B1 (ko) 2002-07-18 2005-01-13 주식회사 하이닉스반도체 플래시 메모리 셀 및 그 제조방법

Also Published As

Publication number Publication date
US9592290B2 (en) 2017-03-14
EP1411962A2 (de) 2004-04-28
US20060228363A1 (en) 2006-10-12
EP1411962A4 (de) 2005-02-02
WO2002074251A3 (en) 2004-02-19
US20150104464A1 (en) 2015-04-16
WO2002074251A9 (en) 2004-05-06
US11001641B2 (en) 2021-05-11
JP2004537976A (ja) 2004-12-24
EP2295064B1 (de) 2017-02-22
US20190100601A1 (en) 2019-04-04
ES2619313T3 (es) 2017-06-26
EP3202790A1 (de) 2017-08-09
WO2002074251A2 (en) 2002-09-26
US8470326B2 (en) 2013-06-25
CA2441042A1 (en) 2002-09-26
DK1411962T3 (da) 2011-04-04
EP1411962B1 (de) 2011-01-19
US9034588B2 (en) 2015-05-19
US20170210816A1 (en) 2017-07-27
DE60238987D1 (de) 2011-03-03
US20110165599A1 (en) 2011-07-07
US20120034227A1 (en) 2012-02-09
ES2358977T3 (es) 2011-05-17
EP2295064A1 (de) 2011-03-16

Similar Documents

Publication Publication Date Title
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE60236646D1 (de) Anti-VEGF-2 Antikörper
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
LU93274I2 (fr) Elotuzumab
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DE60142614D1 (de) Inität
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
GEP20074222B (en) Antibodies to cd40
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
UA92504C2 (en) Anti-myostatin monoclonal antibody
ATE480566T1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE60208534D1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties